




RealRate

PHARMACEUTICAL 2019

Aptevo Therapeutics Inc.
Rank 241 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

Aptevo Therapeutics Inc.
Rank 241 of 371



The relative strengths and weaknesses of Aptevo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptevo Therapeutics Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Aptevo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is -265%, being 66% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	48,689
Cost of Goods Sold	0
Intangible Assets	5,250
Liabilities, Current	17,610
Liabilities, Non-Current	19,478
Other Assets	8,353
Other Compr. Net Income	105
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,024
Property and Equipment	5,202
Research and Development	35,385
Revenues	23,067
Selling, General and Administrative Expense	28,133

Output Variable	Value in 1000 USD
Assets	67,494
Liabilities	37,088
Expenses	63,518
Stockholders Equity	30,406
Net Income	-42,475
Comprehensive Net Income	-42,422
Economic Capital Ratio	-265%

